The company's revenue trajectory has effectively evaporated, with a 100% year-over-year decline in 2026Q1 and historical operating margins reaching as low as -19415.62%.
Endovia Health Sciences, Inc. (EDVA) annual income statement — 13-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | -360.98K | 73.07K | 4.16M | 18.85M | 18.09M | 11.32M | 2.3M | 1.02M | 1.31M | 895.35K | 1.01M | 897.34K | 605.9K | 475.25K |
| Revenue Growth % | -118% | -98.24% | -77.96% | 4.22% | 59.84% | 391.97% | 125.98% | -22.25% | 46.22% | -11.55% | 12.81% | 48.1% | 27.49% | - |
| Cost of Goods Sold | 271.73K | 56.17K | 3.8M | 13.28M | 12.17M | 8.73M | 1.94M | 508.87K | 605.27K | 440.42K | 484.91K | 426.98K | 256.06K | 236.27K |
| COGS % of Revenue | - | 76.87% | 91.45% | 70.46% | 67.28% | 77.19% | 84.19% | 50% | 46.23% | 49.19% | 47.9% | 47.58% | 42.26% | 49.71% |
| Gross Profit | -632.71K | 16.9K | 355.45K | 5.57M | 5.92M | 2.58M | 363.59K | 508.96K | 703.9K | 454.93K | 527.38K | 470.36K | 349.85K | 238.98K |
| Gross Margin % | 175.27% | 23.13% | 8.55% | 29.54% | 32.72% | 22.81% | 15.81% | 50% | 53.77% | 50.81% | 52.1% | 52.42% | 57.74% | 50.29% |
| Gross Profit Growth % | - | -95.25% | -93.62% | -5.92% | 129.27% | 610.02% | -28.56% | -27.69% | 54.73% | -13.74% | 12.12% | 34.45% | 46.39% | - |
| Operating Expenses | 12.9M | 14.2M | 16.4M | 20.86M | 27.31M | 31.66M | 18.03M | 979.36K | 637.23K | 612.13K | 577.38K | 451.46K | 377.72K | 238.37K |
| OpEx % of Revenue | - | 19438.75% | 394.73% | 110.64% | 151.01% | 279.82% | 783.67% | 96.22% | 48.67% | 68.37% | 57.04% | 50.31% | 62.34% | 50.16% |
| Selling, General & Admin | 3.29M | 13.44M | 15.47M | 19.45M | 25.81M | 30.08M | 12.42M | 915.6K | 3M | 1.07M | 521.62K | 421.7K | 349.63K | 236.45K |
| SG&A % of Revenue | - | 18397.99% | 372.38% | 103.2% | 142.68% | 265.82% | 539.93% | 89.96% | 229.39% | 119.91% | 51.53% | 46.99% | 57.7% | 49.75% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1.7M | 760.45K | 928.38K | 1.4M | 1.51M | 1.58M | 5.61M | 63.76K | 62.83K | 71.92K | 55.76K | 29.76K | 28.09K | 1.91K |
| Operating Income | -13.54M | -14.19M | -16.05M | -15.29M | -21.39M | -29.08M | -17.66M | -470.4K | 66.67K | -157.21K | -50K | 18.9K | -27.88K | 618 |
| Operating Margin % | 3750.19% | -19415.62% | -386.17% | -81.1% | -118.28% | -257.01% | -767.86% | -46.22% | 5.09% | -17.56% | -4.94% | 2.11% | -4.6% | 0.13% |
| Operating Income Growth % | - | 11.59% | -4.97% | 28.55% | 26.44% | -64.67% | -3654.66% | -805.51% | 142.41% | -214.41% | -364.57% | 167.79% | -4611% | - |
| EBITDA | -13.32M | -14.18M | -15.51M | -14.74M | -20.45M | -28.85M | -17.52M | -397.42K | 129.5K | -85.29K | 5.76K | 43.04K | -1.5K | 2.53K |
| EBITDA Margin % | 3689.66% | -19402.92% | -373.17% | -78.2% | -113.09% | -254.97% | -761.9% | -39.05% | 9.89% | -9.53% | 0.57% | 4.8% | -0.25% | 0.53% |
| EBITDA Growth % | -7.19% | 8.57% | -5.19% | 27.93% | 29.11% | -64.64% | -4309.59% | -406.89% | 251.84% | -1580.97% | -86.62% | 2975.08% | -159.17% | - |
| D&A (Non-Cash Add-back) | 218.48K | 9.28K | 540.3K | 545.98K | 940.11K | 230.27K | 137.15K | 72.97K | 62.83K | 71.92K | 55.76K | 24.14K | 26.38K | 1.91K |
| EBIT | -13.77M | -19.98M | -16.38M | -15.31M | -21.39M | -28.9M | -17.61M | -4.47M | 73.92K | -143.07K | -44.17K | 24.52K | -26.17K | 618 |
| Net Interest Income | 1.77M | -4.37M | -7.38M | -5.69M | -245.43K | -442.16K | -1.98M | -7.88K | -5.71K | -4.46K | -4.67K | -5.37K | -3.92K | -3.86K |
| Interest Income | 6 | 0 | 1.99K | 2.63K | 6.07K | 643 | 8 | 501 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | -1.77M | 4.37M | 7.38M | 5.69M | 251.5K | 442.81K | 1.98M | 8.38K | 5.71K | 4.46K | 4.67K | 5.37K | 3.92K | 3.86K |
| Other Income/Expense | -2.81M | -10.16M | -7.71M | -5.72M | -245.43K | -262.45K | -1.93M | -6.84K | 1.53K | 9.67K | 1.16K | 254 | -2.21K | -3.86K |
| Pretax Income | -16.35M | -24.35M | -23.76M | -21M | -21.64M | -29.35M | -19.59M | -477.23K | 68.21K | -147.53K | -48.85K | 19.15K | -30.09K | -3.24K |
| Pretax Margin % | 4529.48% | -33325.04% | -571.73% | -111.42% | -119.64% | -259.33% | -851.62% | -46.89% | 5.21% | -16.48% | -4.83% | 2.13% | -4.97% | -0.68% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -17.28M | -25.23M | -23.76M | -21M | -21.84M | -29.05M | -28.67M | -5.14M | 68.21K | -147.53K | -48.85K | 19.15K | -30.09K | -3.24K |
| Net Margin % | 4787.65% | -34537.04% | -571.73% | -111.42% | -120.74% | -256.72% | -1246.65% | -504.57% | 5.21% | -16.48% | -4.83% | 2.13% | -4.97% | -0.68% |
| Net Income Growth % | 33.28% | -6.22% | -13.11% | 3.83% | 24.82% | -1.31% | -458.33% | -7629.73% | 146.23% | -202.04% | -355.03% | 163.65% | -828.1% | - |
| Net Income (Continuing) | -16.35M | -24.35M | -23.76M | -21M | -21.64M | -29.35M | -19.59M | -477.23K | 68.21K | -147.53K | -48.85K | 19.15K | -30.09K | -3.24K |
| Discontinued Operations | -46.39K | -885.56K | 0 | 0 | -199.15K | 294.55K | -9.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.64 | -47.88 | -70.72 | -79.17 | -92.60 | -160.83 | -19.84 | -0.48 | 0.07 | -0.16 | -0.05 | 0.01 | -0.01 | -0.00 |
| EPS Growth % | 57.2% | 32.3% | 10.67% | 14.5% | 42.42% | -710.64% | -4033.33% | -766.67% | 145.92% | -201.54% | - | - | - | - |
| EPS (Basic) | - | -47.88 | -70.72 | -79.17 | -92.60 | -160.83 | -19.84 | -0.48 | 0.07 | -0.16 | -0.05 | 0.01 | -0.01 | -0.00 |
| Diluted Shares Outstanding | 3.06M | 544.6K | 334.61K | 265.31K | 233.69K | 180.63K | 38.62K | 24.61K | 23.72K | 23.49K | 23.49K | 3.76M | 3.76M | 3.76M |
| Basic Shares Outstanding | 3.06M | 544.6K | 334.61K | 265.31K | 233.69K | 180.63K | 38.62K | 24.53K | 23.72K | 23.47K | 23.49K | 3.76M | 3.76M | 3.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying EDVA stock.
For fiscal year 2025, Endovia Health Sciences, Inc. (EDVA) reported total revenue of $0.1M. This represents a 84.6% decline compared to $0.5M in 2013.
Endovia Health Sciences, Inc. (EDVA) reported a net loss of $25.2M for the fiscal year ending 2025.
Endovia Health Sciences, Inc. (EDVA) reported an operating income of $-14.2M, resulting in an operating profit margin of -19415.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Endovia Health Sciences, Inc. (EDVA) generated $0.0M in gross profit for the year, representing a gross profit margin of 23.1%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Imminent Going Concern Risk
Metrics are mathematically derived from official filings.
Revenue Base Effectively Evaporated
As reported in recent financial filings, SBEV's revenue trajectory has collapsed to near-zero levels, with a 100% year-over-year decline in the most recent quarter, signaling a fundamental breakdown in the company's ability to maintain retail distribution or generate meaningful transactional volume across its beverage portfolio.
The transition from multi-million dollar quarterly revenue to essentially zero suggests that the company has lost its core retail accounts or experienced a total failure in its supply chain. This rapid deterioration implies that the brand incubator model has failed to achieve the necessary sales velocity to remain a viable commercial entity.
Structural Margin Erosion Persists
Based on the provided income statement data, SBEV's gross margin has frequently dipped into negative territory, reflecting a distressed cost structure where the company is unable to cover the basic production costs of its alcoholic and non-alcoholic beverage offerings in a competitive retail environment.
The inability to maintain positive gross margins indicates a lack of pricing power and significant inefficiencies in co-packing agreements. Investors should monitor whether the company can ever achieve the scale required to offset fixed costs, as current figures suggest the business model is fundamentally uncompetitive against established beverage peers.
Operating Leverage Remains Deeply Negative
According to the company's historical income statements, operating losses have consistently outpaced any potential gross profit, with the most recent periods showing an operating margin of -19415.62%, which highlights an unsustainable reliance on external capital to fund basic corporate overhead and licensing obligations.
The company's inability to scale operating income relative to its cost base suggests that SG&A expenses are not being managed in alignment with the collapsing revenue. This disconnect implies that the current corporate structure is far too heavy for the minimal volume of business being transacted.
Earnings Quality Obscured by Volatility
As evidenced by the erratic net income figures and significant stock-based compensation fluctuations, the quality of SBEV's reported earnings is extremely low, with non-operating items and massive impairments likely masking the true extent of the company's ongoing cash burn and operational deterioration.
The presence of large, inconsistent stock-based compensation charges alongside deep net losses suggests that equity dilution is being used to compensate for a lack of operational cash flow. Analysts should treat the reported net income as a poor proxy for performance, focusing instead on the persistent and widening gap between revenue and cash outflows.
Viability Challenges to Going Concern
Based on the reported figures, the most significant risk to the investment thesis is the company's near-total loss of revenue combined with a cash balance of only $281,435, which suggests that SBEV may face an imminent liquidity crisis without immediate and highly dilutive capital intervention.
Short-sellers would likely focus on the disconnect between the company's brand-heavy marketing narrative and the reality of its collapsing retail footprint. The lack of a clear path to profitability, combined with the depletion of cash reserves, warrants extreme caution regarding the company's ability to continue as a going concern.